UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials

Journal of hepatology, 2023-10, Vol.79 (4), p.924-932

2023

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

Clinical infectious diseases, 2024-07

2024

Volltextzugriff (PDF)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Open forum infectious diseases, 2023-08, Vol.10 (8), p.ofad354-ofad354

2023

Volltextzugriff (PDF)

Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection

Open forum infectious diseases, 2015-04, Vol.2 (2), p.ofv056-ofv056

2015

Volltextzugriff (PDF)

177 The Effect of Donor Race On Survival of Hepatitis C-Positive African American Liver Transplant Patients

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-795-A-795

2009

Volltextzugriff (PDF)

Seeking Aesculapius

JAMA : the journal of the American Medical Association, 1997-08, Vol.278 (8), p.610

Pang, Phillip S.

1997

Volltextzugriff (PDF)

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1

Clinical infectious diseases, 2016-08, Vol.63 (4), p.528-531

2016

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study

The Lancet infectious diseases, 2015-07, Vol.15 (9), p.1049-1054

2015

Volltextzugriff (PDF)

Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients With Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-Infected Patients

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

1671Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients With Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-Infected Patients

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S454-S454

2015

Volltextzugriff (PDF)

727Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S29-S30

2015

Volltextzugriff (PDF)

1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis

Open forum infectious diseases, 2014-12, Vol.1 (suppl_1), p.S42-S42

2014

Volltextzugriff (PDF)

Attribution of Pediatric Acute Gastroenteritis Episodes and Emergency Department Visits to Norovirus Genogroups I and II

The Journal of infectious diseases, 2021-02, Vol.223 (3), p.452-461

2021

Volltextzugriff (PDF)

N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study

Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.1191-1200

2018

Volltextzugriff (PDF)

Delirium and its association with short-term outcomes in younger and older patients with acute heart failure

PloS one, 2022-07, Vol.17 (7), p.e0270889-e0270889

2022

Volltextzugriff (PDF)

Lung Ultrasound-Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF): A Randomized Controlled Pilot Trial

JACC. Heart failure, 2021-09, Vol.9 (9), p.638-648

2021

Volltextzugriff (PDF)

A Clinical Epidemiology and Molecular Attribution Evaluation of Adenoviruses in Pediatric Acute Gastroenteritis: a Case-Control Study

Journal of clinical microbiology, 2020-12, Vol.59 (1)

2020

Volltextzugriff (PDF)

ACUTE HEART FAILURE VASODILATOR TRIALS REQUIRE HIGHER ENROLLMENT BLOOD PRESSURES TO IDENTIFY THOSE WHO MAY BENEFIT

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.892-892

2021

Volltextzugriff (PDF)

IS SYSTOLIC BLOOD PRESSURE AN APPROPRIATE ENTRY CRITERIA FOR VASODILATOR CLINICAL TRIALS IN ACUTE HEART FAILURE?

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.815-815

2021

Volltextzugriff (PDF)

FUROSEMIDE-RELATED HYPOTENSION IS RARE IN THE MAJORITY OF PATIENTS TREATED FOR ACUTE HEART FAILURE

Journal of the American College of Cardiology, 2024-04, Vol.83 (13), p.336-336

2024

Volltextzugriff (PDF)

Comparative Evaluation of Enteric Bacterial Culture and a Molecular Multiplex Syndromic Panel in Children with Acute Gastroenteritis

Journal of clinical microbiology, 2019-06, Vol.57 (6)

2019

Volltextzugriff (PDF)

Mpeg1 is not essential for antibacterial or antiviral immunity, but is implicated in antigen presentation

Immunology and cell biology, 2022-08, Vol.100 (7), p.529-546

2022

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(84)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection

177 The Effect of Donor Race On Survival of Hepatitis C-Positive African American Liver Transplant Patients

Seeking Aesculapius

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1

Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study

Directly Acting Triple Drug Anti-HCV Therapy Induces Sustained Virologic Response with a Six Week Regimen: A Proof of Concept Phase 2a Cohort Study

Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients With Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-Infected Patients

Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir

1671Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients With Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-Infected Patients

727Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir

1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis

Intramuscular Versus Intravenous SARS-CoV-2 Neutralising Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomised Non-Inferiority Clinical Trial

Attribution of Pediatric Acute Gastroenteritis Episodes and Emergency Department Visits to Norovirus Genogroups I and II

N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study

Delirium and its association with short-term outcomes in younger and older patients with acute heart failure

Lung Ultrasound-Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF): A Randomized Controlled Pilot Trial

A Clinical Epidemiology and Molecular Attribution Evaluation of Adenoviruses in Pediatric Acute Gastroenteritis: a Case-Control Study

ACUTE HEART FAILURE VASODILATOR TRIALS REQUIRE HIGHER ENROLLMENT BLOOD PRESSURES TO IDENTIFY THOSE WHO MAY BENEFIT

IS SYSTOLIC BLOOD PRESSURE AN APPROPRIATE ENTRY CRITERIA FOR VASODILATOR CLINICAL TRIALS IN ACUTE HEART FAILURE?

FUROSEMIDE-RELATED HYPOTENSION IS RARE IN THE MAJORITY OF PATIENTS TREATED FOR ACUTE HEART FAILURE

Comparative Evaluation of Enteric Bacterial Culture and a Molecular Multiplex Syndromic Panel in Children with Acute Gastroenteritis

Mpeg1 is not essential for antibacterial or antiviral immunity, but is implicated in antigen presentation

Aktive Filter

Suchergebnisse filtern